Seattle Genetics Presents New Data on Adcetris at European Symposium

At the 9th International Symposium on Hodgkin Lymphoma (ISHL), Seattle Genetics has highlighted a number of data presentations related it its antibody drug conjugate, Adcetris.

The symposium was held over the weekend of Oct. 12-15, 2013 in Cologne, Germany.

Adcetris is an antibody-drug conjugate that targets the CD30 protein, expressed on the cell surface in both Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. The European Commission granted conditional marketing authorization to Seattle Genetics for Adcetris in October of 2012 for the treatment of relapsed or refractory Hodgkin's and systemic anaplastic large cell lymphoma.

Establishing a 'foundation therapy'

Said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics:

We are evaluating Adcetris broadly in more than 20 ongoing clinical trials, including four global phase 3 trials in earlier lines of therapy for HL and mature T-cell lymphoma, as well as relapsed cutaneous T-cell lymphoma. Our goal is to establish Adcetris as the foundation of therapy for CD30-positive malignancies and improve the therapeutic outcome for patients.

In a step towards achieving those ends, the company presented three oral and nine poster presentations illustrating the broad clinical development program for Adcetris against Hodgkin's. These presentations included data from a phase 1 frontline advanced disease trial and a poster presentation describing the ongoing global phase III 'ECHELON-1' clinical trial in frontline Hodgkin's.

Adcetris remains a second-line therapy for Hodgkin's treatment, a status Seattle Genetics would like to see changed.

Source: ISHL

More Articles

More Articles

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...

Secondary cancers are cancers that develop as a result of chemotherapy and/or...

One of the greatest fears of lymphoma survivors is that they’ll relapse and have to undergo treatment again. This fear is normal but awful to...

Over the years, various classification systems have been used to differentiate lymphoma types including the Rappaport Classification (used until...

If you are new to this website or are looking for guidance to a specific page, here is a list of links to articles that can help you. The "Main...

Often the one who makes the first diagnosis of Hodgkin's Lymphoma / Disease is the person affected. There are some...

Lymphedema is abnormal swelling due to the presence of excess lymphatic fluid within the tissues. This swelling occurs when the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Advances in the treatment of Hodgkin's lymphoma have resulted in remarkable survival rates, even for...